#United States #New York #Actinium Pharmaceuticals #oncology pipeline #Steffen Heeger

Actinium Pharmaceuticals Welcomes Dr. Steffen Heeger as Chief Medical Officer

In a significant step towards enhancing its development pipeline, Actinium Pharmaceuticals, Inc. announced the appointment of Dr. Steffen Heeger, MD, MSc as Chief Medical Officer on June 1, 2026. Dr. Heeger, renowned for his expertise in oncology and radiotherapy, brings a wealth of experience to the role aimed at propelling the company’s oncology pipeline, including the advancement of innovative cancer therapies.

A Track Record of Success

Dr. Heeger comes to Actinium with an impressive background, having held Chief Medical Officer positions in several publicly listed oncology firms. His notable accomplishments include leading the clinical development and worldwide approval of Erbitux®, a groundbreaking treatment, at Merck KGaA; its successful journey to blockbuster status reflects his capability in navigating complex clinical challenges. Beyond this, his tenure at NBE Therapeutics saw the company acquired for a staggering $1.4 billion under his leadership, showcasing his ability to translate promising clinical research into marketable products.

At his most recent position with Full-Life Technologies, Dr. Heeger oversaw the development of a radiotherapy pipeline that included a PSMA-targeting program relevant to Actinium’s ATNM-400 asset, positioning him well to contribute to Actinium's ambitious goals.

Strategic Timing for Actinium

As Actinium looks to further its objectives, Dr. Heeger's appointment is perfectly timed to tackle key upcoming milestones. CEO Sandesh Seth expressed confidence in Dr. Heeger’s unique capability to unlock the value of its therapeutic pipeline. The combination of Dr. Heeger’s operational rigor and clinical expertise is expected to facilitate the advancement of Actimab-A, ATNM-400, and Iomab-ACT, all crucial candidates for upcoming clinical trials and data disclosures in the latter part of 2026.

Focus on Innovative Therapies

The potential of Actinium’s pipeline underpins its strategic focus on targeted radiotherapy, aiming to enhance treatment options for patients with limited choices. Dr. Heeger pointed out that Actinium's assets are highly differentiated, with each possessing the potential for blockbuster status. ATNM-400, targeting a novel antigen distinct from PSMA, and Actimab-A's promising effectiveness in treating relapsed acute myeloid leukemia are prime examples of the groundbreaking work happening at Actinium. Iomab-ACT, designed for cell and gene therapy conditioning, further underscores the company's commit to innovative cancer treatment methodologies.

A Promising Future

With a strong educational background, including an MD and Master of Healthcare Management from the University of Heidelberg, Dr. Heeger’s scientific expertise extends to numerous peer-reviewed publications and pioneering research in alpha-radiotherapy. His experience not only bridges academia and practical application but also aligns with Actinium's commitment to pushing the boundaries of cancer therapies.

Actinium Pharmaceuticals is well-positioned with Dr. Heeger at the helm of its clinical development. As the company progresses towards its pivotal clinical trial phases and data releases, the foundational work laid down by their new CMO is expected to elevate Actinium’s status within the oncology landscape, offering hope to patients facing daunting cancer diagnoses.

For more information about Actinium’s innovative approaches to cancer treatment, visit Actinium Pharmaceuticals' website.